Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids
Public ClinicalTrials.gov record NCT02323646. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids
Study identification
- NCT ID
- NCT02323646
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Enrollment
- 42 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- Telapristone Acetate Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 47 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 11, 2015
- Primary completion
- Apr 5, 2017
- Completion
- Apr 5, 2017
- Last update posted
- Jun 24, 2019
2015 – 2017
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Fort Lauderdale | Florida | 33316 | — |
| Not listed | Sandy Springs | Georgia | 30328 | — |
| Not listed | Metairie | Louisiana | 70001 | — |
| Not listed | Saginaw | Michigan | 48604 | — |
| Not listed | Raleigh | North Carolina | 27612 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | Houston | Texas | 77054 | — |
| Not listed | Richmond | Virginia | 23235-4759 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02323646, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 24, 2019 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02323646 live on ClinicalTrials.gov.